INT14701

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 1983
Last Reported 2011
Negated 1
Speculated 3
Reported most in Abstract
Documents 118
Total Number 122
Disease Relevance 84.19
Pain Relevance 20.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
T cells 3
leukocyte 2
macrophage 1
liver 1
spinal cord 1
IFNA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 1375 100.00 Very High Very High Very High
Inflammation 1061 100.00 Very High Very High Very High
Inflammatory mediators 27 100.00 Very High Very High Very High
Paracetamol 7 100.00 Very High Very High Very High
Morphine 39 99.98 Very High Very High Very High
narcan 7 99.98 Very High Very High Very High
rheumatoid arthritis 1050 99.74 Very High Very High Very High
Arthritis 344 99.64 Very High Very High Very High
Neuritis 8 99.58 Very High Very High Very High
chemokine 166 99.56 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hepatitis C Virus Infection 1215 100.00 Very High Very High Very High
INFLAMMATION 1087 100.00 Very High Very High Very High
Hepatitis 162 100.00 Very High Very High Very High
Dengue 316 99.98 Very High Very High Very High
Respiratory Syncytial Virus 204 99.98 Very High Very High Very High
Pancreatic Cancer 18 99.98 Very High Very High Very High
Hepatotoxicity 56 99.90 Very High Very High Very High
Sarcoma 9 99.90 Very High Very High Very High
Neutropenia 38 99.88 Very High Very High Very High
Chronic Hepatitis 82 99.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Bevacizumab plus IFN is well tolerated, with dose reduction of IFN providing the flexibility to improve tolerability further.
Negative_regulation (reduction) of IFN
1) Confidence 0.54 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721410 Disease Relevance 0.99 Pain Relevance 0
Naloxone blocks the interferon-alpha induced changes in hypothalamic neuronal activity.
Negative_regulation (blocks) of interferon-alpha in neuronal associated with narcan
2) Confidence 0.43 Published 1987 Journal Neurosci. Lett. Section Title Doc Link 3696505 Disease Relevance 0 Pain Relevance 0.31
IFN dosage was not reduced for leukopenia, but in one patient reduction was necessary for thrombopenia, resulting from insufficient marrow reserve after a previous autologous bone marrow transfusion.
Neg (not) Negative_regulation (reduced) of IFN in bone marrow associated with leukopenia and thrombocytopenia
3) Confidence 0.43 Published 1990 Journal Eur. J. Cancer Section Abstract Doc Link 2141493 Disease Relevance 0.79 Pain Relevance 0.09
Three patients, negative for human immunodeficiency virus (HIV), with histologically and polymerase chain reaction-proven non-HIV Kaposi's sarcoma who received low-dose interferon (IFN) as first-line treatment because of disseminated symptomatic disease are reported.
Negative_regulation (received) of IFN associated with sarcoma, acquired immune deficiency syndrome or hiv infection and disease
4) Confidence 0.43 Published 1998 Journal Br. J. Dermatol. Section Abstract Doc Link 9990371 Disease Relevance 1.11 Pain Relevance 0.07
Three patients, negative for human immunodeficiency virus (HIV), with histologically and polymerase chain reaction-proven non-HIV Kaposi's sarcoma who received low-dose interferon (IFN) as first-line treatment because of disseminated symptomatic disease are reported.
Negative_regulation (received) of interferon associated with sarcoma, acquired immune deficiency syndrome or hiv infection and disease
5) Confidence 0.43 Published 1998 Journal Br. J. Dermatol. Section Abstract Doc Link 9990371 Disease Relevance 1.10 Pain Relevance 0.07
Although serum amylase and lipase levels increased after readministration of IFN-alpha, treatment was continued.
Negative_regulation (readministration) of IFN-alpha
6) Confidence 0.42 Published 2000 Journal Gastroenterology Section Abstract Doc Link 10889173 Disease Relevance 0.85 Pain Relevance 0.09
is exemplified in experimental models of arthritis, whereby genetic disruption of the IFN-?
Negative_regulation (disruption) of IFN associated with arthritis
7) Confidence 0.42 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888198 Disease Relevance 1.55 Pain Relevance 0.59
level and normalized the downregulation of the irradiation-induced IFN-?
Negative_regulation (downregulation) of IFN
8) Confidence 0.42 Published 2010 Journal PPAR Research Section Body Doc Link PMC2796461 Disease Relevance 0.59 Pain Relevance 0.26
The effectiveness of interferon (IFN) therapy in malignant lymphoma is analyzed in this review.
Negative_regulation (effectiveness) of IFN associated with lymphatic system cancer
9) Confidence 0.42 Published 1990 Journal J. Invest. Dermatol. Section Abstract Doc Link 1701808 Disease Relevance 0.68 Pain Relevance 0.08
The effectiveness of interferon (IFN) therapy in malignant lymphoma is analyzed in this review.
Negative_regulation (effectiveness) of interferon associated with lymphatic system cancer
10) Confidence 0.42 Published 1990 Journal J. Invest. Dermatol. Section Abstract Doc Link 1701808 Disease Relevance 0.68 Pain Relevance 0.08
Female VPA rats exhibited only increased repetitive/stereotypic-like activity and decreased IFN-gamma/IL-10 ratio.
Negative_regulation (decreased) of IFN
11) Confidence 0.41 Published 2008 Journal Psychoneuroendocrinology Section Abstract Doc Link 18396377 Disease Relevance 0.38 Pain Relevance 0.11
ligand treatment, is associated with decreased IFN-?
Negative_regulation (decreased) of IFN
12) Confidence 0.41 Published 2010 Journal PPAR Research Section Body Doc Link PMC2796461 Disease Relevance 0.33 Pain Relevance 0.22
-deficient (IFN-?
Negative_regulation (deficient) of IFN
13) Confidence 0.41 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888198 Disease Relevance 0.17 Pain Relevance 0.25
For example, it appears that morphine inhibits the interferon (IFN)-alpha, -beta, and -gamma-mediated natural antiviral defense pathways in human peripheral blood mononuclear cells (PBMC).
Negative_regulation (inhibits) of IFN in PBMC associated with morphine
14) Confidence 0.41 Published 2002 Journal J. Acquir. Immune Defic. Syndr. Section Abstract Doc Link 12048358 Disease Relevance 0.57 Pain Relevance 0.46
The suppression of clinical EAN was associated with inhibition of the inflammatory cytokines IFN-gamma and TNF-alpha, as well as the enhancement of anti-inflammatory cytokine IL-4 in lymph node cells and periphery nerve tissues, respectively, in a dose-dependent manner.
Negative_regulation (inhibition) of IFN in nerve associated with inflammation, neuritis and cytokine
15) Confidence 0.41 Published 2002 Journal Neuropharmacology Section Abstract Doc Link 11985832 Disease Relevance 1.10 Pain Relevance 0.94
If grades II-III toxicity occurred, IFN dose was reduced and drug continued at the previous dose level.
Negative_regulation (reduced) of IFN associated with toxicity
16) Confidence 0.40 Published 1994 Journal Am. J. Clin. Oncol. Section Abstract Doc Link 8311014 Disease Relevance 1.26 Pain Relevance 0
This indicates that IFN dose reduction allows tolerability to be managed while the efficacy of the bevacizumab plus IFN regimen is maintained.
Negative_regulation (reduction) of IFN
17) Confidence 0.40 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721410 Disease Relevance 0.13 Pain Relevance 0
The combination of bevacizumab plus IFN provides physicians with a flexible treatment regimen for metastatic RCC and allows the reduction of IFN dose to improve tolerance and manage toxicity without compromising efficacy.


Negative_regulation (reduction) of IFN associated with toxicity, renal cancer and tolerance
18) Confidence 0.39 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721410 Disease Relevance 0.42 Pain Relevance 0.05
CALGB 90206: a second phase III trial of bevacizumab plus IFN in metastatic RCC
Negative_regulation (bevacizumab) of IFN associated with renal cancer
19) Confidence 0.39 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721410 Disease Relevance 0.71 Pain Relevance 0
The dose of IFN, which was initiated at 9 MIU 3 times a week in these trials, can be reduced to effectively manage IFN-related side effects without compromising the efficacy of bevacizumab plus IFN.
Negative_regulation (reduced) of IFN
20) Confidence 0.39 Published 2008 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC2721410 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox